Screening for gestational disorders

Details Screening for gestational disorders Screening for gestational disorders

2004-09-23

2008-03-18

Kemmerer, Elizabeth C. (Department: 1649)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C436S804000, C436S809000, C435S007100

Reexamination Certificate

active

07344892

ABSTRACT:
The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy.

REFERENCES:
patent: 5580554 (1996-12-01), Keith
patent: 6461830 (2002-10-01), Parrott
patent: 2002/0102530 (2002-08-01), Keith, Jr. et al.
patent: 2002/0110833 (2002-08-01), Caniggia et al.
patent: WO 98/28006 (1998-07-01), None
Moutquin et al. (CMAJ. 1997; 157:907-919).
Barden et al. Clin Sci (Lond). 1999; 97:475-83.
Lal et al. Drug Discov Today. Sep. 15, 2002; 18: S143-S148.
merck.com/mmhe/sec22/ch258/ch258c.html; accessed May 23, 2007; 10 pages.
Ong et al. Journal Reprod Med. 2004; 49: 477-480.
Liu et al. Zhonghua Fu Chan Ke Za Zhi. Jan. 2001;36(1):5-8—article in Chinese, translation provided.
Seely and Solomon, “Insulin Resistance and its Potential Role in Pregnancy-Induced Hypertension,”The Journal of Clinical Endocrinology&Metabolism, vol. 88(6), pp. 2393-2398, (2003).
Levine et al., “Circulating Angiogenic Factors and the Risk of Preeclampsia,”The New England Journal of Medicine, vol. 350, pp. 672-683, (2004).
Polliotti et al., “Second-Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early-Onset Preeclampsia,”The American College of Obstetricians and Gynecologists, vol. 101, No. 6, pp. 1266-1274, (2003).
Taylor et al., “Longitudinal Serum Concentrations of Placental Growth Factor: Evidence for Abnormal Placental Angiogenesis in Pathologic Pregnancies,”American Journal Obstetricians and Gynecologists, vol. 188, pp. 177-182 (2003).
Thadhani et al., “Insulin Resistance and Alternations in Angiogenesis Additive Insults That May Lead to Preeclampsia,”Hypertension, vol. 43, pp. 988-992, (2004).
Tidwell et al., “Low Material Serum Levels of Placenta Growth Factor as an Antecedent of Clinical Preeclampsia,”American Journal Obstetricians and Gynecologists, vol. 184, pp. 1267-1272 (2001).
Wolf et al., “First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study,”The Journal of Clinical Endocrinology&Metabolism, vol. 87(4), pp. 1563-1568, (2002).
Wolf et al., “Insulin Resistance But Not Inflammation is Associated with Gestational Hypertension,”Hypertension, vol. 40, pp. 886-891, (2002).
Wolf et al., “Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogensis and Insulin Resistance,”The Journal of Clinical Endocrinology&Metabolism, vol. 89(12), pp. 6239-6243, (2004).
Rinehart et al., “Expression of the Placental Cytokines Tumor Necrosis Factor α, Interleukin 1β, and Interleukin 10 is Increased in Preeclampsia,”Am J Obstet Gynecol, Oct. 1999, pp. 915-920.
Thadhani et al., “First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia,”The journal of Clinical Endocrinology&Metabolism, 89(2), pp. 770-775, (add date).
Maynard et al., “Excess Placental Solube Fms-Like Tyrosine Kinase 1 (sFlt1) may Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia,”The Journal of Clinical Investigation, Mar. 2003, vol. 111, No. 5, pp. 1-10.
Page et al., “Placental Peptides as Markers of Gestational Disease,”Reproduction(2002) 123, 487-495.
Masséet al., “A Prospective Study of Several Potential Biologic Markers for Early Prediction of the Development of Preeclampsia,”Am J Obstet Gynecol, vol. 169, No. 3, pp. 501-508.
Heikkinen et al., “Cytokine Levels in Midtrimester Amniotic Fluid in Normal Pregnancy and in the Prediction of Pre-Eclampsia,”Scand. J. Immunol.53, 310-314, 2001.
Helske et al., “Expression of Vascular Endothelial Growth Factor Receptors 1, 2 and 3 in Placentas From Normal and Complicated Pregnancies,”Molecular Human Reproduction, vol. 7, No. 2, pp. 205-210, 2001.
Acromite, “Androgens in preeclampsia,” Am. J. Obstet. Gynecol. 180(1 Pt 1):60-3 (1999), abstract only.
Izumi et al., “Calcium-to-creatinine ratio in spot urine samples in early pregnancy and its relation to the development of preeclampsia,” Metabolism. 46(10):1107-8 (1997), abstract only.
Serin et al., “Androgen levels of preeclamptic patients in the third trimester of pregnancy and six weeks after delivery,” Acta Obstet. Gynecol Scand. 80(11):1009-13 (2001), abstract only.
Van den Elzen, “Serum lipids in early pregnancy and risk of pre-eclampsia,” Br. J. Obstet. Gynaecol. 103(2):117-22 (1996), abstract only.
Wolf et al., “Obesity and preeclampsia: the potential role of inflammation,” Obstet. Gyencol. 98(5 Pt 1):757-62 (2001), abstract only.

Affiliated with

Also associated with

Rating

Screening for gestational disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Screening for gestational disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening for gestational disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3972406